Presentation is loading. Please wait.

Presentation is loading. Please wait.

Giuseppe Biondi Zoccai, MD, FSICI-GISE University of Turin, Turin, Italy.

Published byJocelyn Peters Modified over 9 years ago

Similar presentations

Presentation on theme: "Giuseppe Biondi Zoccai, MD, FSICI-GISE University of Turin, Turin, Italy."— Presentation transcript:

1 Giuseppe Biondi Zoccai, MD, FSICI-GISE University of Turin, Turin, Italy

2  Scope of the problem  Second generation drug-eluting stents  Update on endothelial progenitor cell capturing stents

3  Scope of the problem  Second generation drug-eluting stents  Update on endothelial progenitor cell capturing stents

4

5 25% Stent Thrombosis !

6

7

8

9  Scope of the problem  Second generation drug-eluting stents  Update on endothelial progenitor cell capturing stents

10

11

12

13

14

15

16

17

18

19

20

21

22

23  Scope of the problem  Second generation drug-eluting stents  Update on endothelial progenitor cell capturing stents

24

25

26

27

28 accelerated endothelialization by EPC-“capturing” immediately after Stent Implantation Endothelialization of the Stent Struts:

29 0 10 20 30 40 50 GenousBMS (%) p=0.07 mean In rabbit iliac model BMSGenous 7-days Anti-CD34 coating

30 Confocal SES-anti-CD34 SES alone 3 days 14 days

31

32 LATIN AMERICA Venezuela 1 MIDDLE EAST Egypt 6 Lebanon 1 Saudi Arabia 1 Syria 3 Turkey 3 EUROPE Austria 8 Belgium 3 Cyprus 2 Denmark 2 France 8 Germany 11 Greece 6 Ireland 1 Italy 26 Netherlands 5 Portugal 3 Spain 8 Switzerland 1 United Kingdom 9 NORTH AFRICA Tunisia 2 ASIA PACIFIC Australia 6 Hong Kong 1 Malaysia 9 Singapore 2 144 SITES Czech Republic 5 Finland 1 Hungary 2 Poland 2 Romania 1 Russian Federation 5

33 Patients treated on or before Feb 22, 2007 All events reported before Aug 12, 2008; all events adjudicated by CEC Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR 30 days6 months12 months Cardiac Death0.6 %1.3 %1.9 % MI1.2 %1.5 %1.6 % Q-wave0.2 % Non Q-wave1.0 %1.3 %1.4 % TLR (Clinically Driven)0.2 %2.9 %5.0 % PCI0.2 %2.6 %4.6 % CABG0.0 %0.3 %0.4 % MACE1.9 %5.8 %8.5 % Acute stent thrombosis0.2 % Sub-acute stent thrombosis0.4 % Late stent thrombosis0.3 %

34 Acute stent thrombosis0.0 % Sub-acute stent thrombosis0.2 % Late stent thrombosis0.8 % 30 days6 months12 months Cardiac Death0.8 %2.5 %3.6 % MI0.6 %1.3 % Q-wave0.1 % Non Q-wave0.5 %1.2 % TLR (Clinically Driven)0.2 %3.2 %4.9 % PCI0.2 %2.8 %4.5 % CABG0.0 %0.4 %0.5 % MACE1.6 %6.9 %9.9 % Patients treated on or before Feb 22, 2007 All events reported before Aug 12, 2008; all events adjudicated by CEC Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR

35 Acute stent thrombosis0.2 % Sub-acute stent thrombosis0.3 % Late stent thrombosis0.4 % 30 days6 months12 months Cardiac Death0.6 %1.2 %1.7 % MI1.1 %1.3 %1.4 % Q-wave0.1 % 0.2 % Non Q-wave0.9 %1.2 % TLR (Clinically Driven)0.2 %3.0 %5.2 % PCI0.2 %2.6 %4.7 % CABG0.0 %0.4 %0.5 % MACE1.8 %5.5 %8.2 % Patients treated on or before Feb 22, 2007 All events reported before Aug 12, 2008; all events adjudicated by CEC Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR

36 Acute stent thrombosis0.4 % Sub-acute stent thrombosis0.7 % Late stent thrombosis0.2 % 30 days6 months12 months Cardiac Death0.5 %2.2 %3.3 % MI1.6 %2.7 %2.5 % Q-wave0.4 %0.5 % Non Q-wave1.3 %2.2 %2.0 % TLR (Clinically Driven)0.4 %2.5 %4.2 % PCI0.4 %2.5 %4.2 % CABG0.0 % MACE2.5 %7.4 %9.9 % Patients treated on or before Feb 22, 2007 All events reported before Aug 12, 2008; all events adjudicated by CEC Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR

37 Genous (e-HEALING) Cypher (LEADERS) BioMatrix (LEADERS) Taxus (SYNTAX) Inclusion criteriaall comers 3-VD / Left main 1 All events reported before Aug 12, 2008; all events adjudicated by CEC; Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR 2 MACE = Cardiac Death, MI TVR; The Lancet, 372: 1163 – 1173, 2008 3 MACE = any death, MI, TVR, Syntax Trial, presented at the ESC meeting in Munich, Sept. 2008 4 ARC definite + probable

38 Genous (e-HEALING) Cypher (LEADERS) BioMatrix (LEADERS) Taxus (SYNTAX) Inclusion criteriaall comers 3-VD / Left main Number of patients3196850857903 Duration of follow-up12 months9 months 12 months 1 All events reported before Aug 12, 2008; all events adjudicated by CEC; Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR 2 MACE = Cardiac Death, MI TVR; The Lancet, 372: 1163 – 1173, 2008 3 MACE = any death, MI, TVR, Syntax Trial, presented at the ESC meeting in Munich, Sept. 2008 4 ARC definite + probable

39 Genous (e-HEALING) Cypher (LEADERS) BioMatrix (LEADERS) Taxus (SYNTAX) Inclusion criteriaall comers 3-VD / Left main Number of patients3196850857903 Duration of follow-up12 months9 months 12 months Cardiac death1.9 % 1 2.5 %1.6 % 4.3 % (any) 1 All events reported before Aug 12, 2008; all events adjudicated by CEC; Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR 2 MACE = Cardiac Death, MI TVR; The Lancet, 372: 1163 – 1173, 2008 3 MACE = any death, MI, TVR, Syntax Trial, presented at the ESC meeting in Munich, Sept. 2008 4 ARC definite + probable

40 Genous (e-HEALING) Cypher (LEADERS) BioMatrix (LEADERS) Taxus (SYNTAX) Inclusion criteriaall comers 3-VD / Left main Number of patients3196850857903 Duration of follow-up12 months9 months 12 months Cardiac death1.9 % 1 2.5 %1.6 % 4.3 % (any) MI1.6 % 1 4.6 %5.7 % 4.8 % 1 All events reported before Aug 12, 2008; all events adjudicated by CEC; Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR 2 MACE = Cardiac Death, MI TVR; The Lancet, 372: 1163 – 1173, 2008 3 MACE = any death, MI, TVR, Syntax Trial, presented at the ESC meeting in Munich, Sept. 2008 4 ARC definite + probable

41 Genous (e-HEALING) Cypher (LEADERS) BioMatrix (LEADERS) Taxus (SYNTAX) Inclusion criteriaall comers 3-VD / Left main Number of patients3196850857903 Duration of follow-up12 months9 months 12 months Cardiac death1.9 % 1 2.5 %1.6 % 4.3 % (any) MI1.6 % 1 4.6 %5.7 % 4.8 % TLR Clinically Driven5.0 % 1 4.9 %4.3 % 13.7 % 1 All events reported before Aug 12, 2008; all events adjudicated by CEC; Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR 2 MACE = Cardiac Death, MI TVR; The Lancet, 372: 1163 – 1173, 2008 3 MACE = any death, MI, TVR, Syntax Trial, presented at the ESC meeting in Munich, Sept. 2008 4 ARC definite + probable

42 Genous (e-HEALING) Cypher (LEADERS) BioMatrix (LEADERS) Taxus (SYNTAX) Inclusion criteriaall comers 3-VD / Left main Number of patients3196850857903 Duration of follow-up12 months9 months 12 months Cardiac death1.9 % 1 2.5 %1.6 % 4.3 % (any) MI1.6 % 1 4.6 %5.7 % 4.8 % TLR Clinically Driven5.0 % 1 4.9 %4.3 % 13.7 % MACE8.5 % 1 10.5 % 2 9.2 % 2 17.2 % 3 1 All events reported before Aug 12, 2008; all events adjudicated by CEC; Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR 2 MACE = Cardiac Death, MI TVR; The Lancet, 372: 1163 – 1173, 2008 3 MACE = any death, MI, TVR, Syntax Trial, presented at the ESC meeting in Munich, Sept. 2008 4 ARC definite + probable

43 1 All events reported before Aug 12, 2008; all events adjudicated by CEC; Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR 2 MACE = Cardiac Death, MI TVR; The Lancet, 372: 1163 – 1173, 2008 3 MACE = any death, MI, TVR, Syntax Trial, presented at the ESC meeting in Munich, Sept. 2008 4 ARC definite + probable Genous (e-HEALING) Cypher (LEADERS) BioMatrix (LEADERS) Taxus (SYNTAX) Inclusion criteriaall comers 3-VD / Left main Number of patients3196850857903 Duration of follow-up12 months9 months 12 months Cardiac death1.9 % 1 2.5 %1.6 % 4.3 % (any) MI1.6 % 1 4.6 %5.7 % 4.8 % TLR Clinically Driven 5.0 % 1 4.9 %4.3 % 13.7 % MACE8.5 % 1 10.5 % 2 9.2 % 2 17.2 % 3 Stent thrombosis1.0 % 4 2.2 % 4 2.7 % 4 3.4 % 4 Recommended dual antiplatelet therapy4 weeks12 months

44

45

46

47

48

49  Study flow chart 2007: 400 P-PCI 100 patients included 100 patients included (Randomization ) 50 Genous TM 50 CrCo 6-month clinical, angio and IVUS FU ASA 100mg/day+clopidogrel 75mg/day 30 days; GPIIb/IIIa inhibitors and thromboaspiration at the discretion of the physician

50  6-month clinical outcome MACE CV Deaths MI TLR ST P=0.03 P=NS P=0.04 P=NS (Non hierachical) Genous TM CrCo 24 10 446 2 14 4 6 0 44 2 2

51  6 month angio and IVUS data Genous Cr-Co P value Genous Cr-Co P value ANGIO DATA N=44 N=47 Late lumen loss (mm) 0.89±0.59 0.79±0.47 NS Late lumen loss (mm) 0.89±0.59 0.79±0.47 NS Restenosis (>50%) 20 13 NS Restenosis (>50%) 20 13 NS (QCA: Pie Medical Im) (QCA: Pie Medical Im) IVUS N=41 N=42 mean in-stent NIH (mm 3 ) 49.7 ± 48 40.0±22.8 NS mean in-stent NIH (mm 3 ) 49.7 ± 48 40.0±22.8 NS (Volcano, pull back 0.5%mm/s) (Volcano, pull back 0.5%mm/s) (QIVA Pie Medical Im) (QIVA Pie Medical Im)

52  Stent thrombosis in Genous TM group P-PCI Day 30 Day 60 ASA ASA+clopidogrel 324852 ARC definition: ARC definition: 3x definite; 3x late Patient Age TIMI Thrombus iGP IIb/IIa Vessel EF Stent Days Treatment Dual T Stát. J.J. 61 3 Y Y RCA 60 1; 2.75/23 48 dPOBA N Alive P.U. 26 3 Y Y LAD 45 1; 3/23 32 dPCI+G Y Alive J.T. 47 2 Y Y RCA 52 2; 3.5/23+18 52 dPOBA N Alive J.T. 47 2 Y Y RCA 52 2; 3.5/23+18 52 dPOBA N Alive

53  Single center trial – (Università degli Studi di Napoli - Federico II)  PI: F. Piscione  195 consecutive patients underwent PCI with either Genous or DES (SES or PES) implantations in the period May – July 2006.  Dual anti-platelet therapy for 1 month post-Genous implant and 9 months post DES implant.  Clinical follow-up (average FU 10.1 ± 3.2 months).  Follow-up major adverse clinical events (MACE): cardiac death, MI, target vessel re-PTCA, CABG.

54 Age Diabetes3234 Smoke 32.750 Dislipidemia 4663 Familyhistory 38.233.4 Pre PTCA Pre CABG 10.9 9.1 15.4 3.8 p 0.047 NS Pre EF45 NS Genous DES Hypertension 70 80.6 NS (n=100) (n=95) Male 0.048 65.56±10.8 60.11±10.8 84 67.7 51 (%)

55 CX (%) 16.326.2 PTCA Multivessel (%) 24.5 26.2 RCA (%) LAD (%) 57 43 p NS 3 73 NS 22.67±9 Lesion length (mm) 3 57 44.6 Genous DES 26.9±12 0.049 Multiple stenting (%) 98.595.4 NS IIb/IIIa (%) TIMI grade post 62 Direct stenting (%) 43.872.3 0.002

56 Genous DES % p=0.045 p=0.013 p=0.017 p=NS

57  Coronary stents have always faced a significant risk of early and late stent thrombosis  Whereas second-generation drug-eluting stents have improved early and subsequent outcomes, their biocompatibility is still at stake  Recent studies on EPC stents suggest the promising role of this device  The asymptotic coronary stent will likely be a bioabsorbable device with drug-elution and EPC capabilities

58

Download ppt "Giuseppe Biondi Zoccai, MD, FSICI-GISE University of Turin, Turin, Italy."

Similar presentations

“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:

“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:
Www. Clinical trial results.org The RAVEL Study A RAndomised (double blind) study with the Sirolimus coated BX™ VElocity balloon expandable stent (CYPHER™)

Www. Clinical trial results.org The RAVEL Study A RAndomised (double blind) study with the Sirolimus coated BX™ VElocity balloon expandable stent (CYPHER™)
Four Drug Eluting Stent Trials Keith D Dawkins MD FRCP FACC Southampton University Hospital Keith D Dawkins MD FRCP FACC Southampton University Hospital.

Four Drug Eluting Stent Trials Keith D Dawkins MD FRCP FACC Southampton University Hospital Keith D Dawkins MD FRCP FACC Southampton University Hospital.
3rd CEEGI Advisory Board1 Resolute in the DES era: Indications & Limitations Georgios I. Papaioannou, MD, MPH, FACC, FSCAI Athens Medical Center Cardiac.

3rd CEEGI Advisory Board1 Resolute in the DES era: Indications & Limitations Georgios I. Papaioannou, MD, MPH, FACC, FSCAI Athens Medical Center Cardiac.
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.

2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
Kenneth W. Mahaffey Daniel M. Wojdyla Stefan K. James Hugo A. Katus Steen Husted Gabriel Steg Christopher P. Cannon Richard C. Becker Claes Held Nardev.

Kenneth W. Mahaffey Daniel M. Wojdyla Stefan K. James Hugo A. Katus Steen Husted Gabriel Steg Christopher P. Cannon Richard C. Becker Claes Held Nardev.
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I

29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
© Lloyd’s Regional Watch Content Guide CLICK ANY BOX AMERICAS IMEA EUROPE ASIA PACIFIC.

© Lloyd’s Regional Watch Content Guide CLICK ANY BOX AMERICAS IMEA EUROPE ASIA PACIFIC.
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,

DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
Clinical Result Overview

Clinical Result Overview
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.

Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.

As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.
BIOSENSORS-CLINICAL UPDATE “LEADERS AND BEYOND” John E Shulze, CTO BIOSENSORS INTERNATIONAL GROUP Jan 29, 2010.

BIOSENSORS-CLINICAL UPDATE “LEADERS AND BEYOND” John E Shulze, CTO BIOSENSORS INTERNATIONAL GROUP Jan 29, 2010.
TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.

TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.
Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.

Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.
Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.

Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.

Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®

The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®
As presented by Keith D Dawkins MD FRCP FACC Southampton University Hospital United Kingdom EuroSTAR The European Cobalt Stent with Antiproliferative for.

As presented by Keith D Dawkins MD FRCP FACC Southampton University Hospital United Kingdom EuroSTAR The European Cobalt Stent with Antiproliferative for.
Left Main Trifurcation Disease: Early and Long-Term Outcomes Of Percutaneous Coronary Intervention I.Sheiban, A.Gerasimou, F. Sciuto, P.Omedè, G. Biondi.

Left Main Trifurcation Disease: Early and Long-Term Outcomes Of Percutaneous Coronary Intervention I.Sheiban, A.Gerasimou, F. Sciuto, P.Omedè, G. Biondi.

Similar presentations

Ads by Google